Use of lipid in amphotericin B infusion has no benefit

On p 379 Schöffski et al present their results of a randomised phase II study comparing the feasibility of treatment with, and safety and toxicity of, amphotericin B 0.75 mg/kg/day in either glucose 5% or intralipid 20%, for the empirical treatment of neutropenic cancer patients with refractory fever of unknown origin or pneumonia. The trial did not confirm previous observations of improved renal toxicity and better tolerance with amphotericin B in intralipid emulsions, but showed potential respiratory complications from self made lipid emulsions. The drug combination has high toxicity and unknown efficacy and should not be given to patients.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study
Patrick Schöffski, Mathias Freund, R Wunder, D Petersen, C H Köhne, H Hecker, U Schubert, and A Ganser
BMJ 1998 317: 379-384. [Abstract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ